Success Metrics

Clinical Success Rate

100.0%

Based on 3 completed trials

Completion Rate

100%(3/3)

Active Trials

2(25%)

Results Posted

0%(0 trials)

Phase Distribution

Ph phase_1

13%

Ph phase_2

63%

Ph phase_3

25%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution8 total trials

Phase 1Safety & dosage

1(12.5%)

Phase 2Efficacy & side effects

5(62.5%)

Phase 3Large-scale testing

2(25.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(2)

Completed(3)

Other(3)

Detailed Status

Completed3

unknown3

Recruiting2

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 3

Trials by Phase

Phase 11 (12.5%)

Phase 25 (62.5%)

Phase 32 (25.0%)

Trials by Status

recruiting225%

completed338%

unknown338%

Recent Activity

2 active trials

Showing 5 of 8

recruitingphase_3

Clinical Trials (8)

Showing 8 of 8 trials

NCT06859788Phase 3

SPI-1005 for the Treatment of Meniere's Disease (Open Label)

Recruiting

NCT06340633Phase 2

SPI-1005 in Adults Receiving Cochlear Implant

Recruiting

NCT04677972Phase 3

SPI-1005 for the Treatment of Meniere's Disease

Completed

NCT04483973Phase 2

SPI-1005 Treatment in Severe COVID-19 Patients

Unknown

NCT04484025Phase 2

SPI-1005 Treatment in Moderate COVID-19 Patients

Unknown

NCT05117710Phase 1

IMPase in Treatment-resistant Depression

Unknown

NCT03013400Phase 2

Ebselen as an add-on Treatment in Hypo/Mania

Completed

NCT00762671Phase 2

Signaling Mechanisms and Vascular Function in Patients With Diabetes Mellitus

Completed

All 8 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 8